(Albany, United States) As per DelveInsight’s assessment, globally, the Geographic Atrophy pipeline constitutes 23+ key companies continuously working towards developing 25+ Geographic Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Geographic Atrophy pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Geographic Atrophy NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the Geographic Atrophy Pipeline treatment landscape of the report, click here @ Geographic Atrophy Pipeline Outlook
Key Takeaways from the Geographic Atrophy Pipeline Report
Geographic Atrophy Overview
Geographic atrophy (GA) is a chronic progressive degeneration of the macula, as part of late-stage age-related macular degeneration (AMD). The disease is characterized by localized sharply demarcated atrophy of outer retinal tissue, retinal pigment epithelium and choriocapillaris.
For further information, refer to the detailed Geographic Atrophy Unmet Needs, click here for Geographic Atrophy Ongoing Clinical Trial Analysis
Geographic Atrophy Emerging Drugs Profile
IONIS-FB-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of complement factor B (FB). Genetic association studies have shown that overaction of this cascade has been associated with the development of several complement-mediated diseases, including dry age-related macular degeneration (AMD). FB, a key regulatory protein, is produced predominately in the liver and circulates at high levels throughout the vascular system, including in capillaries in the eye.
Zimura (avacincaptad pegol) is an investigational drug product designed to target and inhibit the cleavage of complement protein C5 and the formation of its downstream fragments, C5a and C5b. By inhibiting the formation of these fragments, Zimura is believed to decrease or slow the chronic inflammation and cell death associated with the retinal aging process by decreasing the formation of membrane attack complex (MAC) and inflammasome activity, thereby potentially avoiding or slowing the degeneration of retinal pigment epithelial cells. This potential mechanism is the rationale for Zimura as a potential therapy for geographic atrophy secondary to age-related macular degeneration.
Geographic Atrophy Pipeline Therapeutics Assessment
There are approx. 23+ key companies which are developing the therapies for Geographic Atrophy. The Geographic Atrophy companies which have their Geographic Atrophy drug candidates in the most advanced stage, i.e. phase III include, IVERIC bio.
Request a sample and discover the recent advances in Geographic Atrophy Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Geographic Atrophy Segmentation
Geographic Atrophy Drugs and Companies
Geographic Atrophy Therapeutics Assessment
Some of the Companies in the Geographic Atrophy Therapeutics Market include-
Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc, Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis, and others.
Dive deep into rich insights for drugs for Geographic Atrophy Pipeline, click here for Geographic Atrophy Unmet Needs and Analyst Views
Scope of the Geographic Atrophy Pipeline Report
Got Queries? Find out the related information on Geographic Atrophy Merger and acquisitions, Licensing Activities
Table of Content
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services